GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Piotroski F-Score

Biolife Sciences (Biolife Sciences) Piotroski F-Score : 0 (As of Jun. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biolife Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Biolife Sciences's Piotroski F-Score or its related term are showing as below:


Biolife Sciences Piotroski F-Score Historical Data

The historical data trend for Biolife Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Piotroski F-Score Chart

Biolife Sciences Annual Data
Trend Nov04 Nov05 Nov06 Nov07
Piotroski F-Score
- - - -

Biolife Sciences Quarterly Data
Nov04 Feb05 May05 Aug05 Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08 May08
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (May08) TTM:Last Year (May07) TTM:
Net Income was -0.362 + -1.028 + -0.446 + -0.842 = $-2.68 Mil.
Cash Flow from Operations was -0.258 + -0.152 + -0.347 + -0.108 = $-0.87 Mil.
Revenue was 2.244 + 2.317 + 1.479 + 1.798 = $7.84 Mil.
Gross Profit was 0.348 + 0.392 + 0.117 + 0.356 = $1.21 Mil.
Average Total Assets from the begining of this year (May07)
to the end of this year (May08) was
(3.602 + 3.505 + 3.762 + 3.174 + 3.041) / 5 = $3.4168 Mil.
Total Assets at the begining of this year (May07) was $3.60 Mil.
Long-Term Debt & Capital Lease Obligation was $0.42 Mil.
Total Current Assets was $0.76 Mil.
Total Current Liabilities was $3.04 Mil.
Net Income was -0.103 + -0.184 + -0.196 + -0.46 = $-0.94 Mil.

Revenue was 2.511 + 2.201 + 1.644 + 2.398 = $8.75 Mil.
Gross Profit was 0.47 + 0.374 + 0.304 + 0.522 = $1.67 Mil.
Average Total Assets from the begining of last year (May06)
to the end of last year (May07) was
(2.656 + 3.244 + 3.474 + 3.326 + 3.602) / 5 = $3.2604 Mil.
Total Assets at the begining of last year (May06) was $2.66 Mil.
Long-Term Debt & Capital Lease Obligation was $2.52 Mil.
Total Current Assets was $1.10 Mil.
Total Current Liabilities was $0.87 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biolife Sciences's current Net Income (TTM) was -2.68. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biolife Sciences's current Cash Flow from Operations (TTM) was -0.87. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (May07)
=-2.678/3.602
=-0.74347585

ROA (Last Year)=Net Income/Total Assets (May06)
=-0.943/2.656
=-0.35504518

Biolife Sciences's return on assets of this year was -0.74347585. Biolife Sciences's return on assets of last year was -0.35504518. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biolife Sciences's current Net Income (TTM) was -2.68. Biolife Sciences's current Cash Flow from Operations (TTM) was -0.87. ==> -0.87 > -2.68 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: May08)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from May07 to May08
=0.421/3.4168
=0.1232147

Gearing (Last Year: May07)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from May06 to May07
=2.518/3.2604
=0.77229788

Biolife Sciences's gearing of this year was 0.1232147. Biolife Sciences's gearing of last year was 0.77229788. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: May08)=Total Current Assets/Total Current Liabilities
=0.755/3.038
=0.24851876

Current Ratio (Last Year: May07)=Total Current Assets/Total Current Liabilities
=1.104/0.87
=1.26896552

Biolife Sciences's current ratio of this year was 0.24851876. Biolife Sciences's current ratio of last year was 1.26896552. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biolife Sciences's number of shares in issue this year was 0.005. Biolife Sciences's number of shares in issue last year was 0.002. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.213/7.838
=0.15475887

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.67/8.754
=0.19076993

Biolife Sciences's gross margin of this year was 0.15475887. Biolife Sciences's gross margin of last year was 0.19076993. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (May07)
=7.838/3.602
=2.17601333

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (May06)
=8.754/2.656
=3.29593373

Biolife Sciences's asset turnover of this year was 2.17601333. Biolife Sciences's asset turnover of last year was 3.29593373. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biolife Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Biolife Sciences  (OTCPK:BLFE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biolife Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolife Sciences (Biolife Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052
Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.
Executives
Arthur Viola director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired 09-15-2020